, Volume 72, Issue 9, pp 1293–1298 | Cite as


First Global Approval
  • Joshuan M. Subramaniam
  • Glenn Whiteside
  • Kate McKeage
  • Jamie C. Croxtall
R&D Insight Profile


Mogamulizumab (Poteligeo®) is a defucosylated, humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). Development is being carried out by its owner Kyowa Hakko Kirin for various haematological malignancies, and by licensee Amgen for asthma. Mogamulizumab was conceived through Kyowa Hakko Kirin’s Potelligent® technology, which produces antibodies with enhanced antibody-dependent cellular cytotoxicity. This is achieved largely by reducing fucose content in the oligosaccharide structure of the Fc region. Mogamulizumab has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukaemia-lymphoma (ATL) and is the first Potelligent® antibody to receive marketing approval anywhere in the world. Phase II development is underway for adult T-cell leukaemia-lymphoma (ATL) and cutaneous T-cell lymphoma in the US, and for peripheral T-cell lymphoma in the US and Europe. Amgen is conducting a phase I US-based study in patients with asthma. This article summarizes the milestones in the development of intravenous mogamulizumab leading to this first approval.


Herpes Zoster Mycosis Fungoides Sezary Syndrome ADCC Activity Fucose Content 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ishida T, Ueda R. Antibody therapy for adult T-cell leukaemia-lymphoma. Int J Hematol 2011; 94: 443–52CrossRefPubMedGoogle Scholar
  2. 2.
    Proietti FA, Carnieiro-Proietti ABF, Catalan-Soares BC, et al. Global epidemiology of HTLV-1 infection and associated diseases. Oncogene 2005; 24: 6058–68CrossRefPubMedGoogle Scholar
  3. 3.
    Kyowa Hakko Kirin Co Ltd. New Drug Application Approval for POTELIGEO® (Mogamulizumab) Injection in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)., 30 Mar 2012
  4. 4.
    Kyowa Hakko Kirin Co Ltd. Kyowa Hakko Kirin submitted New Drug Application in Japan for KW-0761, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)., 26 Apr 2011
  5. 5.
    Kyowa Hakko Kirin Co Ltd. Kyowa Hakko Kirin Announces Results from Japan Phase 2 Clinical Trial of KW-0761 (Anti-CCR4 Humanized Monoclonal Antibody) in Patients with Recurrent or Relapsed Adult T-Cell Leukemia-Lymphoma (ATL)., 07 Dec 2010
  6. 6.
    Kyowa Hakko Kogyo Co Ltd, Kirin Pharma Company Limited, Kirin Holdings Company Limited. Strategic Alliance Between Kyowa Hakko Group and Kirin Group Maximizing Synergy Through an Alliance Centered Around the Pharmaceutical Business., 22 Oct 2007
  7. 7.
    Kyowa Hakko Kogyo Co Ltd, Amgen. Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody., 06 Mar 2008
  8. 8.
  9. 9.
    Ishii T, Ishida T, Utsunomiya A et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukaemia/lymphoma. Clin Cancer Res 2010; 16: 1520–31CrossRefPubMedGoogle Scholar
  10. 10.
    Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res 2004; 10: 7529–39CrossRefPubMedGoogle Scholar
  11. 11.
    Yano H, Ishida T, Inagaki A, et al. Defucosylated anti-CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory mycosis fungoides and Sezary syndrome. Clin Cancer Res 2007; 13: 6494–500CrossRefPubMedGoogle Scholar
  12. 12.
    Ito A, Ishida T, Utsunomiya A, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2Rγnull mice in vivo. J Immunol 2009; 183: 4782–91CrossRefPubMedGoogle Scholar
  13. 13.
    Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonclonal antibody (KW-0761) for relapsed adult T-cell leukaemia-lymphoma: a multicentre phase II study. J Clin Oncol 2012 March 10; 30 (8): 837–42CrossRefPubMedGoogle Scholar
  14. 14.
    Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28 (9): 1591–8CrossRefPubMedGoogle Scholar
  15. 15.
    Duvic M, Pinter-Brown L, Foss FM et al. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 962Google Scholar
  16. 16.
    Kyowa Medex Co Ltd. Kyowa Medex Receives Approval for POTELIGEO® TEST IHC and POTELIGEO® TEST FCM, Companion Diagnostics of POTELIGEO® Injection in Japan., 30 Mar 2012
  17. 17.
    Kyowa Medex Co Ltd. Kyowa Medex Submitted New Drug Application for In Vitro Diagnostic Reagent to Detect CCR4 Proteins in Japan., 26 Apr 2011

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Joshuan M. Subramaniam
    • 1
  • Glenn Whiteside
    • 1
  • Kate McKeage
    • 2
  • Jamie C. Croxtall
    • 2
  1. 1.Adis R&D InsightAucklandNew Zealand
  2. 2.AdisAucklandNew Zealand

Personalised recommendations